Novo Nordisk For the period January 1, 2024 to September 30, 2024. YTD Revenues: $30.6 billion (+23%) YTD Earnings: $10.9 billion (+18%)   Comments: Sales within Diabetes and Obesity care increased by 25% to $28.7 billion, mainly driven by GLP-1 diabetes sales growth of 25% and Obesity care growing by 44%. Rare disease sales increased by 3% to $1.9 billion. Ozempic sales were up 32% to $12.9 billion. Wegovy sales were up 76% to $5.7 billion. Sales in North America increased by 31% and Intern...